世界の抗体薬物複合体（ADC）製造市場予測　2024-2032年

出版：Inkwood Research（インクウッドリサーチ）　出版年月：2024年5月

GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET FORECAST 2024-2032

世界の抗体薬物複合体（ADC）製造市場予測　2024-2032年

[myphp file=”contact”]　　出版社・価格・納期について

Inkwood Researchでは世界の下記地域・国別の市場調査レポートも出版しています。各レポートの詳細についてはお問合せください。

Report Overview

KEY FINDINGS

The global antibody drug conjugates contract manufacturing market is estimated to progress at a CAGR of 12.47% during the forecast period 2024-2032.

世界の抗体薬物複合体（ADC）製造市場は、2024年から2032年の予測期間中に12.47%のCAGRで成長すると推定されています。

Numerous aspects stimulate the market growth: the rising demand for targeted therapies, the growing inclination towards contract manufacturing companies as an economical choice, the surging global cancer incidence, and advancements in drug conjugation technologies.

MARKET INSIGHTS

The global antibody drug conjugates contract manufacturing market is experiencing significant growth driven by the rising demand for targeted cancer therapies and personalized medicine. ADCs represent a promising class of biopharmaceuticals that combine the specificity of monoclonal antibodies with the cytotoxicity of small-molecule drugs, offering enhanced efficacy and reduced side effects. This has led to increased research and development activities in the field of ADCs, creating a robust demand for contract manufacturing services.
Contract manufacturing organizations (CMOs) specializing in ADC production play a crucial role in supporting pharmaceutical companies in the development and commercialization of ADC therapies. These CMOs offer a range of services, including process development, scale-up, manufacturing, quality control, and regulatory support. Their expertise in bioconjugation techniques, linker chemistry, and analytical testing ensures the efficient production of high-quality ADCs meeting regulatory standards.
The global antibody drug conjugates contract manufacturing market is characterized by partnerships and collaborations between pharmaceutical companies and CMOs to leverage each other’s strengths and capabilities. This collaboration model enables pharmaceutical companies to access specialized manufacturing expertise and infrastructure without substantial investments in building in-house ADC manufacturing capabilities. It also allows for flexibility in production scale, optimizing resources and reducing time-to-market for ADC therapies.

REGIONAL INSIGHTS

The global antibody drug conjugates contract manufacturing market growth analysis includes the geographical assessment of Asia-Pacific, Europe, North America, and Rest of World. North America is expected to be the eminent region in the global antibody drug conjugates contract manufacturing market. In the region, leading pharmaceutical companies such as AbbVie and Catalent, along with established CMOs, possess deep expertise in complex manufacturing processes, including ADCs. The region benefits from a strong biopharmaceutical supply chain, modern facilities, skilled labor, and government backing, driving growth in the ADCs contract manufacturing sector.

REPORT SYNOPSIS

COMPETITIVE INSIGHTS

The global antibody drug conjugates contract manufacturing market exhibits intense rivalry among key players, driven by competition to offer advanced bioconjugation techniques, scalable production capacities, regulatory compliance, and cost-effective solutions. This competition fosters innovation, quality enhancements, and strategic partnerships to capture market share and meet the growing demand for targeted cancer therapies. Some of the eminent players in the market include Sterling Pharma Solutions, Recipharm AB, Lonza Group, Piramal Pharma Solutions, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)
2.5.2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING DEMAND FOR TARGETED THERAPIES
3.1.2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE
3.1.3. SURGING GLOBAL CANCER INCIDENCE
3.1.4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING
3.2.2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS
3.2.3. STRINGENT REGULATORY REQUIREMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING DEMAND FOR ADCS
4.1.2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
4.3.2. GROWTH PROSPECT MAPPING FOR EUROPE
4.3.3. GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
4.3.4. GROWTH PROSPECT MAPPING FOR REST OF WORLD
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. KEY BUYING CRITERIA
4.6.1. EXPERTISE AND EXPERIENCE
4.6.2. MANUFACTURING CAPACITY
4.6.3. REGULATORY COMPLIANCE
4.6.4. QUALITY CONTROL
4.6.5. COST
4.7. REGULATORY FRAMEWORK
5. MARKET BY PHASE
5.1. CLINICAL PHASE
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. COMMERCIAL PHASE
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
6. MARKET BY LINKER
6.1. CLEAVABLE LINKERS
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. NON-CLEAVABLE LINKERS
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
7. MARKET BY CONDITION
7.1. MYELOMA
7.1.1. MARKET FORECAST FIGURE
7.1.2. SEGMENT ANALYSIS
7.2. LYMPHOMA
7.2.1. MARKET FORECAST FIGURE
7.2.2. SEGMENT ANALYSIS
7.3. BREAST CANCER
7.3.1. MARKET FORECAST FIGURE
7.3.2. SEGMENT ANALYSIS
7.4. OTHER CONDITIONS
7.4.1. MARKET FORECAST FIGURE
7.4.2. SEGMENT ANALYSIS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.1.3. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.1.4. KEY PLAYERS IN NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.1.5. COUNTRY ANALYSIS
8.1.5.1. UNITED STATES
8.1.5.1.1. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.1.5.2. CANADA
8.1.5.2.1. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
8.2.1. MARKET SIZE & ESTIMATES
8.2.2. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.2.3. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.2.4. KEY PLAYERS IN EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.2.5. COUNTRY ANALYSIS
8.2.5.1. UNITED KINGDOM
8.2.5.1.1. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.2. GERMANY
8.2.5.2.1. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.3. FRANCE
8.2.5.3.1. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.4. ITALY
8.2.5.4.1. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.5. SPAIN
8.2.5.5.1. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.6. SWITZERLAND
8.2.5.6.1. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.7. NORDIC COUNTRIES
8.2.5.7.1. NORDIC COUNTRIES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.8. REST OF EUROPE
8.2.5.8.1. REST OF EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
8.3.1. MARKET SIZE & ESTIMATES
8.3.2. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.3.3. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.3.4. KEY PLAYERS IN ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.3.5. COUNTRY ANALYSIS
8.3.5.1. CHINA
8.3.5.1.1. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.2. JAPAN
8.3.5.2.1. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.3. INDIA
8.3.5.3.1. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.4. SOUTH KOREA
8.3.5.4.1. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.5. THAILAND
8.3.5.5.1. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.6. AUSTRALIA & NEW ZEALAND
8.3.5.6.1. AUSTRALIA & NEW ZEALAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.7. REST OF ASIA-PACIFIC
8.3.5.7.1. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
8.4.1. MARKET SIZE & ESTIMATES
8.4.2. REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.4.3. REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.4.4. KEY PLAYERS IN REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.4.5. REGIONAL ANALYSIS
8.4.5.1. LATIN AMERICA
8.4.5.1.1. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.4.5.2. MIDDLE EAST & AFRICA
8.4.5.2.1. MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.2. COMPANY PROFILES
9.2.1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. SERVICES LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. CAMBREX CORPORATION
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. SERVICES LIST
9.2.3. CATALENT INC
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. SERVICES LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. CERBIOS-PHARMA SA
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. SERVICES LIST
9.2.5. LONZA GROUP
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. SERVICES LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. MERCK KGAA
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. SERVICES LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. PIRAMAL PHARMA SOLUTIONS
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. SERVICES LIST
9.2.7.3. STRENGTHS & CHALLENGES
9.2.8. RECIPHARM AB
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. SERVICES LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. SARTORIUS AG
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. SERVICES LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. SAMSUNG BIOLOGICS CO LTD
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. SERVICES LIST
9.2.10.3. STRENGTHS & CHALLENGES
9.2.11. STERLING PHARMA SOLUTIONS
9.2.11.1. COMPANY OVERVIEW
9.2.11.2. SERVICES LIST
9.2.11.3. STRENGTHS & CHALLENGES
9.2.12. WUXI BIOLOGICS
9.2.12.1. COMPANY OVERVIEW
9.2.12.2. SERVICES LIST
9.2.12.3. STRENGTHS & CHALLENGES

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: GLOBAL CLINICAL PHASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: GLOBAL CLINICAL PHASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: GLOBAL COMMERCIAL PHASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: GLOBAL COMMERCIAL PHASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 9: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 10: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 11: GLOBAL CLEAVABLE LINKERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 12: GLOBAL CLEAVABLE LINKERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 13: GLOBAL NON-CLEAVABLE LINKERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 14: GLOBAL NON-CLEAVABLE LINKERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 15: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 16: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 17: GLOBAL MYELOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 18: GLOBAL MYELOMA MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 19: GLOBAL LYMPHOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 20: GLOBAL LYMPHOMA MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 21: GLOBAL BREAST CANCER MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 22: GLOBAL BREAST CANCER MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 23: GLOBAL OTHER CONDITIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 24: GLOBAL OTHER CONDITIONS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 25: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 26: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 27: NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 28: NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 29: KEY PLAYERS OPERATING IN NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
TABLE 30: EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 31: EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 32: KEY PLAYERS OPERATING IN EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
TABLE 33: ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 34: ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 35: KEY PLAYERS OPERATING IN ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
TABLE 36: REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 37: REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 38: KEY PLAYERS OPERATING IN REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
TABLE 39: LIST OF MERGERS & ACQUISITIONS
TABLE 40: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 41: LIST OF PARTNERSHIPS & AGREEMENTS

List of Figures

LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA
FIGURE 4: GROWTH PROSPECT MAPPING FOR EUROPE
FIGURE 5: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
FIGURE 6: GROWTH PROSPECT MAPPING FOR REST OF WORLD
FIGURE 7: MARKET MATURITY ANALYSIS
FIGURE 8: MARKET CONCENTRATION ANALYSIS
FIGURE 9: KEY BUYING CRITERIA
FIGURE 10: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY PHASE, IN 2023
FIGURE 11: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLINICAL PHASE, 2024-2032 (IN $ MILLION)
FIGURE 12: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COMMERCIAL PHASE, 2024-2032 (IN $ MILLION)
FIGURE 13: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY LINKER, IN 2023
FIGURE 14: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)
FIGURE 15: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY NON-CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)
FIGURE 16: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY CONDITION, IN 2023
FIGURE 17: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY MYELOMA, 2024-2032 (IN $ MILLION)
FIGURE 18: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LYMPHOMA, 2024-2032 (IN $ MILLION)
FIGURE 19: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)
FIGURE 20: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY OTHER CONDITIONS, 2024-2032 (IN $ MILLION)
FIGURE 21: NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 22: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 23: CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 24: EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 25: UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 26: GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 27: FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 28: ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 29: SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 30: SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 31: NORDIC COUNTRIES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 32: REST OF EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 33: ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 34: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 35: JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 36: INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 37: SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 38: THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 39: AUSTRALIA & NEW ZEALAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 40: REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 41: REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)
FIGURE 42: LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)
FIGURE 43: MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)